NCT04680936

Brief Summary

Lateral epicondylitis (tennis elbow) is an enthesopathy seen in 1-2% of the population aged 30-65 years, which can occur in the lateral epicondyle origo of the extensor carpi radialis brevis and longus muscles, after frequently repetitive activities and can lead to limitations in the daily life activities of the patients. The diagnosis is made by anamnesis and clinical examination, cases that last more than 3 months are defined as chronic lateral epicondylitis. Treatment options are analgesics, non-steroidal anti-inflammatory drugs, hand-wrist splints, eccentric strengthening exercises for forearm muscles and wrist dorsiflexors, injection therapies, physical therapy agents such as therapeutic ultrasound, ESWT(extracorporeal shockwave therapy), low-level laser therapy, and surgery. Prolotherapy is a treatment method that is performed with repetitive injections of a small amount of irritant or sclerosing solutions such as hypertonic dextrose, phenol-glycerin-glucose, or sodium morrhuate and aims to activate the healing process by increasing the blood flow around the damaged tendinopathy or enthesopathy area with the effect of these solutions. Hypertonic dextrose solutions in concentrations ranging from 12.5-20% are frequently used in prolotherapy. Prolotherapy can be done with ultrasound guidance or by determining anatomical landmarks. The injection is applied to the annular ligament, lateral epicondyle, and supracondylar area where the forearm extensor muscles adhere. Injection side effects and complications are pain, bruising, muscle spasm, nerve or vessel damage at the injection site. Based on previous studies, the low dose of dextrose solutions (1%, 5%, and 10%) may have a similar effect with fewer side effects than higher concentrations of dextrose solutions (15%, 20%, 25%) and the low dose may have fewer cell damage. Thus, it may be possible to apply an effective treatment method with fewer side effects in the treatment of lateral epicondylitis. Also, in this study, the effect of inflammation created by injection of saline in one group and the inflammatory, proliferative and angiogenic effects of dextrose injected in other groups at different concentrations on the treatment outcome will be compared.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 13, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 23, 2020

Completed
9 days until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 21, 2022

Completed
Last Updated

May 26, 2022

Status Verified

May 1, 2022

Enrollment Period

1.3 years

First QC Date

December 13, 2020

Last Update Submit

May 21, 2022

Conditions

Keywords

prolotherapydextrose prolotherapytennis elbowchronic lateral epicondylitisdextrose therapy

Outcome Measures

Primary Outcomes (4)

  • Evaluation of the effect of prolotherapy injection on hand grip strength.

    Evaluation of the effect of prolotherapy injection on hand grip strength Hand grip strength will be measured with Hand-Dynamometer, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).

    Change of the hand grip strength at baseline, 3 weeks and after the injection treatment (12th week).

  • Evaluation of elbow pain that develops at rest and movement before, during and after injection treatment.

    Elbow pain at rest and movement will be assessed by Visual Analogue Scale, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).

    Change in elbow pain at baseline, 3 weeks and after the injection treatment (12th week).

  • Evaluation of elbow pain threshold, before, during and after injection treatment.

    Elbow pain threshold will be assessed by Pain Algometer, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).

    Change in elbow pain threshold at baseline, 3 weeks and after the injection treatment (12th week).

  • Assessment of the effect of elbow pain on daily life activities.

    Daily life activities will be measured with Quick-DASH(Disabilities of Arm, Shoulder and Hand) Questionnaire, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).

    Change of the effect of elbow pain on daily life activities at baseline, 3 weeks and after the injection treatment (12th week).

Secondary Outcomes (2)

  • Evaluation of the clinical improvement.

    week 3 and 12

  • Evaluation of the injection side effects and complications.

    12 weeks

Study Arms (3)

low dose dextrose arm (5% dextrose)

ACTIVE COMPARATOR

Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.

Drug: Dextrose 5% in water

high dose dextrose arm (15% dextrose)

ACTIVE COMPARATOR

Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.

Drug: Dextrose 15 % in Water

Isotonic saline arm (0.9% NaCl)

ACTIVE COMPARATOR

Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.

Drug: Isotonic sodium chloride solution

Interventions

low dose dextrose solution

Also known as: 5% dextrose solution
low dose dextrose arm (5% dextrose)

high dose dextrose solution

Also known as: 15%dextrose solution
high dose dextrose arm (15% dextrose)

isotonic saline solution

Also known as: 0.9% NaCl solution
Isotonic saline arm (0.9% NaCl)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Those who admit Kirsehir Ahi Evran University Hospital and is diagnosed with lateral epicondylitis,
  • Participants with unilateral or bilateral lateral epicondylitis and pain and functional limitations due to this condition,
  • who can read and write in Turkish,
  • participant's admission participating in the study,

You may not qualify if:

  • receiving any injection therapy to the elbow area in the last 3 months,
  • participants with complaints less than 3 months(acute lateral epicondylitis)
  • previously surgery on the elbow area,
  • having a history of acute trauma or fracture in the elbow area,
  • have local dermatological problems,
  • have a local infection in the treatment area,
  • those who are allergic to dextrose,
  • with coagulation disorders or using anticoagulant drugs,
  • with an autoimmune disease,
  • with type 1 or type 2 diabetes mellitus,
  • have unregulated hypertension,
  • have immune dysfunction,
  • with malignancy or diagnosed with a malignancy in the last 5 years,
  • pregnancy or lactation,
  • having cervical radiculopathy in the same extremity,
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kirsehir Ahi Evran University Hospital

Kırşehir, Turkey (Türkiye)

Location

Related Publications (4)

  • Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016 Jul 7;9:139-59. doi: 10.4137/CMAMD.S39160. eCollection 2016.

    PMID: 27429562BACKGROUND
  • Tsai SW, Hsu YJ, Lee MC, Huang HE, Huang CC, Tung YT. Effects of dextrose prolotherapy on contusion-induced muscle injuries in mice. Int J Med Sci. 2018 Jul 30;15(11):1251-1259. doi: 10.7150/ijms.24170. eCollection 2018.

    PMID: 30123064BACKGROUND
  • Sims SE, Miller K, Elfar JC, Hammert WC. Non-surgical treatment of lateral epicondylitis: a systematic review of randomized controlled trials. Hand (N Y). 2014 Dec;9(4):419-46. doi: 10.1007/s11552-014-9642-x.

    PMID: 25414603BACKGROUND
  • Ciftci YGD, Tuncay F, Kocak FA, Okcu M. Is Low-Dose Dextrose Prolotherapy as Effective as High-Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis? A Double-Blind, Ultrasound Guided, Randomized Controlled Study. Arch Phys Med Rehabil. 2023 Feb;104(2):179-187. doi: 10.1016/j.apmr.2022.09.017. Epub 2022 Oct 13.

MeSH Terms

Conditions

Tennis Elbow

Interventions

GlucoseWaterSodium ChlorideSaline Solution

Condition Hierarchy (Ancestors)

Elbow TendinopathyTendinopathyMuscular DiseasesMusculoskeletal DiseasesElbow InjuriesArm InjuriesWounds and InjuriesTendon Injuries

Intervention Hierarchy (Ancestors)

HexosesMonosaccharidesSugarsCarbohydratesHydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen CompoundsChloridesHydrochloric AcidChlorine CompoundsSodium CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • FIGEN TUNCAY, PROF.,M.D.

    Kirsehir Ahi Evran Universitesi

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
Double-Blind Study
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
RESIDENT OF PHYSICAL MEDICINE AND REHABILITATION

Study Record Dates

First Submitted

December 13, 2020

First Posted

December 23, 2020

Study Start

January 1, 2021

Primary Completion

May 1, 2022

Study Completion

May 21, 2022

Last Updated

May 26, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations